(From Reuters AlertNet). One can hope that ever more attention given to successful commercialization of stem cell therapies outside the US will lead to some reduction in stifling regulation within the US. Certainly advocacy groups - such as FasterCures - should be making hay with the success of TheraVitae. "Theravitae is set to begin clinical trials with Thai doctors in January to treat peripheral vascular disease, a circulatory ailment which can lead to amputations. Next up: Parkinson's disease by mid-2006 and some forms of blindness in the first quarter of 2007. Eventually, Theravitae thinks, the technology could be used to treat emphysema, broken bones, renal failure and diabetes. ... Theravitae, which says it will become profitable in January 2006, expects 100 people a month will be coming to Thailand to seek the stem cell treatment by June next year."
05
Jan
2006
More TheraVitae Press Attention
Comments
Post a comment; thoughtful, considered opinions are valued. Please note that comments incorporating ad hominem attacks, advertising, and other forms of inappropriate behavior are likely to be deleted.
First Steps
The Causes of Aging
- Accumulating AGEs
- Buildup of Amyloid Between Cells
- The Failing Adaptive Immune System
- The Failing Innate Immune System
- Declining Lysosomal Function
- Mitochondrial DNA Damage
- Nuclear DNA Damage
- Buildup of Senescent Cells
- Other Causes of Aging
Archives and Feeds
- Monthly News and Blog Archives
- Newsletter Archive
- Using the Fight Aging! Content Feeds
- Fight Aging! on the Kindle
Required Reading
- Calorie Restriction
- The Community, Visualized
- Cryonics
- Engineered Negligible Senescence
- Envisaging a World Without the FDA
- How to Argue for Longevity Science
- Introductory Articles
- The Odds of Human Longevity Mutations
- The Need For Activism and Advocacy
- Stem Cells, Regenerative Medicine
- Twelve Ways to Extend Mouse Life Span
- Transhumanism and Human Longevity
- The Vital Debate in Aging Research
- What is Anti-Aging?
Creative Commons
- All of Fight Aging!, with the exception of the introductory articles, is published under the Creative Commons Attribution 3.0 license. In short, this means that you are encouraged to republish and rewrite Creative Commons licensed Fight Aging! content in any way you see fit, the only requirements being that you (a) link to the original, (b) attribute the author, and (c) attribute Fight Aging!.